EntryPoint Capital LLC Makes New Investment in Mirum Pharmaceuticals, Inc. $MIRM

EntryPoint Capital LLC acquired a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the first quarter, HoldingsChannel.com reports. The fund acquired 9,675 shares of the company’s stock, valued at approximately $436,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of MIRM. GAMMA Investing LLC lifted its stake in shares of Mirum Pharmaceuticals by 4,555.0% in the first quarter. GAMMA Investing LLC now owns 5,586 shares of the company’s stock worth $252,000 after acquiring an additional 5,466 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Mirum Pharmaceuticals by 174.9% in the first quarter. SG Americas Securities LLC now owns 19,182 shares of the company’s stock worth $864,000 after acquiring an additional 12,204 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Mirum Pharmaceuticals by 2.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 16,685 shares of the company’s stock worth $752,000 after acquiring an additional 339 shares in the last quarter. MPM Bioimpact LLC lifted its stake in shares of Mirum Pharmaceuticals by 19.7% in the fourth quarter. MPM Bioimpact LLC now owns 589,579 shares of the company’s stock worth $24,379,000 after acquiring an additional 96,856 shares in the last quarter. Finally, KBC Group NV acquired a new position in shares of Mirum Pharmaceuticals in the first quarter worth about $89,000.

Mirum Pharmaceuticals Stock Up 2.4%

Shares of Mirum Pharmaceuticals stock opened at $66.71 on Thursday. The company has a quick ratio of 2.97, a current ratio of 3.13 and a debt-to-equity ratio of 1.21. The firm has a market cap of $3.35 billion, a P/E ratio of -55.13 and a beta of 0.94. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.86 and a fifty-two week high of $69.27. The business has a 50-day moving average price of $53.97 and a 200 day moving average price of $48.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%.The company had revenue of $127.79 million during the quarter, compared to the consensus estimate of $107.91 million. During the same period in the previous year, the firm posted ($0.52) earnings per share. Mirum Pharmaceuticals’s quarterly revenue was up 64.1% compared to the same quarter last year. On average, sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $62.00, for a total value of $2,480,000.00. Following the completion of the transaction, the chief executive officer directly owned 138,641 shares in the company, valued at $8,595,742. The trade was a 22.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Jolanda Howe sold 10,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $58.00, for a total value of $580,000.00. Following the completion of the transaction, the senior vice president owned 2,426 shares of the company’s stock, valued at approximately $140,708. The trade was a 80.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 91,041 shares of company stock valued at $5,320,624. 14.36% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. HC Wainwright boosted their price target on Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 7th. JMP Securities set a $81.00 price target on Mirum Pharmaceuticals and gave the stock a “market outperform” rating in a research note on Thursday, August 7th. Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Evercore ISI boosted their price objective on Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Finally, Stifel Nicolaus set a $89.00 price objective on Mirum Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average target price of $74.13.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.